STOCKSCOUTER

StockScouter Premium

StockScouter Screener and Portfolios are now in our premium offering.
Learn more or Get it now! Stockscouter Portfolio performance

ICPT INTERCEPT PHARMACEUTICALS INCORPORATED StockScouter® Report

4

StockScouter® Score

INTERCEPT PHARMACEUTICALS INCORPORATED, a small cap value company in the healthcare sector, is expected to slightly underperform the market over the next six months with slightly higher than average risk

10 is the best possible rating. Learn more.

Summary

Positives

  • Earnings growth in the past year has accelerated moderately compared to earnings growth in the past three years. Positive
  • The most recent quarterly earnings report higher than analysts’ consensus forecast. Positive

 

Concerns

  • The multi-period measure of relative price change and consistency is well below average. Negative
  • Moving average analysis for ICPT suggests weak price movement over the medium term. Negative

 

Short-term Outlook

Over the next 1-2 months, StockScouter forecasts that small cap stocks will be neutral, value stocks will be neutral, and healthcare stocks will be neutral.

Expected Risk/Return

Progress: 80% done.
Progress: 40% done.
Low
High

Core Model Grades

A
C
C
F

Previous Ratings

5
5
5